Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Eva Domingo-Domenech; Barbara Pro; Tim Illidge; Steven Horwitz; Lorenz Trümper; Swami Iyer; Ranjana Advani; Nancy L. Bartlett; Jacob Haaber Christensen; Won-Seog Kim; Tatyana Feldman; Ilseung Choi; G. Gritti; David Belada; Andrei R. Shustov; Arpad Illes; P. L. Zinzani; Andreas Hüttmann; Marek Trneny; Steven Le Gouill; Deepa Jagadeesh; Jonathan W. Friedberg; Meredith Little; Cassie Dong; Michelle A. Fanale; Keenan Fenton; Kerry J. Savage

doi:10.1038/s41408-025-01432-4

Key Points

Overall survival significantly improved with brentuximab vedotin plus chemotherapy, marking a positive impact on treatment outcomes.
Five-year follow-up revealed favorable results for younger patients receiving this combined therapy over chemotherapy alone.
Subgroup analysis focused on various demographics and risk factors to assess treatment efficacy and safety parameters.
Findings highlight the effectiveness of brentuximab vedotin in enhancing survival prospects for anaplastic large cell lymphoma patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Subgroup analysis demonstrates improved treatment outcomes in patients with anaplastic large cell lymphoma, suggesting potential benefits of combined therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Domingo-Domenech et al. (2026) studied this question.

synapsesocial.com/papers/69a75d27c6e9836116a26b6d https://doi.org/10.1038/s41408-025-01432-4

View Full Paper

Ask AI

Bookmark

Share

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading